POM3
PreclinicalSmall molecule
POM3 is one of 46 small molecule programs targeting Hypertriglyceridemia. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
63 competitors in Hypertriglyceridemia
#DrugCompanyPhaseTrials
1Selzentry
GSKApproved
Cipro
BayerApproved
Lopid
PfizerApproved
Lovaza
AstraZenecaApproved
Zocor
OOrganon and Co
Approved
Topamax
WWim Janssens
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Zetia
OOrganon and Co
Phase 3
Statin
Bristol-Myers SquibbPhase 3
EVKEEZA
RegeneronPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for POM3. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- PProvident Clinical Research